http://medicalxpress.com/ en-us Medical Xpress internet news portal provides the latest news on Health and Medicine. British health authorities said on Wednesday they would not recommend Jakavi, a drug produced by Swiss pharmaceutical company Novartis to treat a rare form of blood cancer, deeming it too expensive. http://medicalxpress.com/news/2013-02-britain-snubs-costly-novartis-blood.html Medications Wed, 13 Feb 2013 05:50:01 EST news279952610 Clear communication between cells is essential to every aspect of the body's internal function. But since cells can't talk, or send emails, how do they communicate? http://medicalxpress.com/news/2013-01-tilt-cell-surface-receptor-cancer.html Cancer Thu, 31 Jan 2013 11:18:33 EST news278853501 Researchers have demonstrated that combination therapy with PU-H71 and ruxolitinib increases the durability and effectiveness of a treatment that had previously shown limited utility for patients with myelofibrosis. http://medicalxpress.com/news/2012-12-combination-therapy-jak2-hsp90-inhibitors.html Cancer Sun, 09 Dec 2012 12:00:03 EST news274274558 Encouraging safety and efficacy data on novel and emerging therapies presented at the 54th Annual Meeting of the American Society of Hematology (ASH) signal an important step forward in the development of treatment strategies for patients with hard-to-treat leukemia, myeloma, and myelofibrosis. http://medicalxpress.com/news/2012-12-therapeutic-agents-patients-hard-to-treat-blood.html Cancer Sun, 09 Dec 2012 11:50:04 EST news274274478 Novartis AG and Incyte Corp. said Tuesday that European Union regulators approved their blood cancer drug Jakavi. http://medicalxpress.com/news/2012-09-eu-novartis-incyte-blood-cancer-drug.html Medications Tue, 04 Sep 2012 08:10:37 EST news265965018 (Medical Xpress) -- New research from Karolinska Institutet shows that the survival for patients with chronic myeloproliferative diseases has improved in recent decades. This is despite the fact that no targeted drugs have yet been registered for this group of diseases. More than 9,000 patients have been included in a unique population-based study which has been published in the Journal of Clinical Oncology. http://medicalxpress.com/news/2012-07-survival-patients-chronic-blood-diseases.html Cancer Tue, 17 Jul 2012 05:52:58 EST news261723169 People with a blood cancer — myelofibrosis — can benefit from a drug called ruxolitinib, according to a randomized, double-blind, placebo-controlled clinical trial that included patients and researchers from the Stanford University School of Medicine. The results of the multi-site phase-3 trial, which will be published in the March 1 issue of the New England Journal of Medicine, led the Food and Drug Administration to approve the drug in November as treatment for people with intermediate or advanced cases of the disease. http://medicalxpress.com/news/2012-02-drug-relief-symptoms-myelofibrosis.html Cancer Wed, 29 Feb 2012 18:17:42 EST news249761839 In a major advance in treatment, a multicenter study found that ruxolinitib did a better job than off-label chemotherapy drugs reducing the terrible symptoms associated with myelofibrosis, including pain, enlarged spleen, anemia, fever, chills, fatigue, and weight loss. The results were presented today at the annual meeting of the American Society of Hematology and Oncology in San Diego. http://medicalxpress.com/news/2011-12-ruxolinitib-myelofibrosis-symptoms.html Cancer Mon, 12 Dec 2011 11:17:27 EST news242911039 The first drug to treat a rare disorder that causes red blood cells to build up inside bone marrow was cleared Wednesday by the Food and Drug Administration http://medicalxpress.com/news/2011-11-fda-drug-bone-marrow-disorder.html Medications Wed, 16 Nov 2011 12:59:10 EST news240670722 (Medical Xpress) -- A new study conducted by a team of researchers at Boston University School of Medicine (BUSM) sheds light on a possible new approach to treat the bone marrow disease known as myelofibrosis by inhibiting an enzyme that connects extracellular fibers. The study, published online in the Journal of Biological Chemistry, was conducted under the direction of Katya Ravid, PhD, professor of medicine and biochemistry and director of the Evans Center for Interdisciplinary Biomedical Research at BUSM. http://medicalxpress.com/news/2011-06-potential-approaches-myelofibrosis.html Medical research Thu, 23 Jun 2011 14:50:48 EST news228059438